Eisai Co Ltd: (OTC: ESALY)

$43.90

-0.15 (-0.34%)

Volume 400

May 17 03:39 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		43.90 - 43.99
	
		52wk Low - High
		39.60 - 46.99
	
		Previous Close
		44.05
	
		Avg. Volume
		1,526
	
		Industry
		MED-DRUGS
	
		Market Cap
		13.02 B
	
		Div - Yield
		1.57 - 3.59
	
		Beta
		0.40
	
		PE (Forward)
		22.86
	
		Current Year Est.
		1.92
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		No Zacks Recommendation
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		88 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of NA

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            22.86
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            1.92
                        
                            Current Quarter Estimate
                            NA
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            05-16-2013
                        
                            EPS Last Year
                            1.75
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America.   
Full ESALY Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ESALY Chart  by YCharts

Earnings Estimates

	Current Qtr (03/2013)	Next Qtr (06/2013)	Current Year (03/2013)	Next Year (03/2014)
Average Estimate	NA	NA	1.72	1.92
Number of Estimates	0	0	1	1
Low Estimate	NA	NA	1.72	1.92
High Estimate	NA	NA	1.72	NA
Year Ago EPS	0.35	0.52	2.47	1.72
EPS Growth	NA	NA	-30.36%	11.63%

More ESALY Estimates

Average Earnings Estimates for ESALY

EPS Growth for ESALY

Industry Analysis

Name	Symbol	Previous Close
EISAI CO LTD	ESALY	43.90
JAZZ PHARMACEUT	JAZZ	58.36
SALIX PHARM-LTD	SLXP	59.28
SANTARUS INC	SNTS	21.91
USANA HLTH SCI	USNA	65.46
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.83
CELL THERAPEUT	CTIC	1.16
CUBIST PHARM	CBST	49.51
ELAN CP PLC ADR	ELN	11.67

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Jazz Pharma Posts Higher Y/Y Earnings

May 14, 2013

Arena Pharma Narrows Loss

May 06, 2013

Data from Novartis' SPARK

Apr 23, 2013

BioLineRx to Start BL-8040 Study

Apr 16, 2013

Patients Dosed in Arena Study

Apr 09, 2013

Arena Cuts Loss, Misses Estimates

Mar 08, 2013

Zacks #5 Rank Additions for Thursday

Jan 10, 2013

Arena Cuts Loss, Affirms Sales View

Nov 09, 2012

More ESALY Zacks Commentary

Financials

EPS TTM	1.75
Sales	8,229
Net Income	546
Price/Earnings	25.09
Price/Book	2.46
Price/Cash Flow	9.84
Price/Sales	1.80

More ESALY Financials

News

Why Arena Pharmaceuticals Shares Slimmed Down - TheMotleyFool

May 3, 2013

Will This Obesity Biotech`s Latest Scheme Boost Sales? - TheMotleyFool

Mar 6, 2013

When Will This Obesity Drug Launch? - TheMotleyFool

Mar 4, 2013

Epizyme, Eisai and Roche to Develop EZH2 Companion Diagnostic - Comtex

Jan 7, 2013

Eisai Granted Additional Six Month U.S. Marketing Exclusivity For ACIPHEXA? (Rabeprazole Sodium) - Comtex

Dec 11, 2012

FDA Grants Orphan Drug Status To Morphotek's Amatuximab (MORAb-009) - Comtex

Nov 14, 2012

The Zacks Analyst Blog Highlights: Novartis, Pfizer, Eisai, Nordstrom and Gap - Comtex

Sep 4, 2012

EMA Accepts Licence Extension Application For Use Of Eisai's Adjunctive Treatment Zonegran(R) (zonisamide) In Children With Partial Onset Epilepsy - Comtex

Jul 10, 2012

See All News Stories on ESALY

Broker Recommendations

Current ABR	4.00
ABR (Last Week)	4.00
# of recs in ABR	2
Average Target Price	40.00
Industry Rank by ABR	88 out of 265
Rank in Industry	17 out of 91

More ESALY Broker Recommendations

Day Low - High	43.90 - 43.99
52wk Low - High	39.60 - 46.99
Previous Close	44.05
Avg. Volume	1,526
Industry	MED-DRUGS
Market Cap	13.02 B
Div - Yield	1.57 - 3.59
Beta	0.40
PE (Forward)	22.86
Current Year Est.	1.92
Quarterly Earnings ESP	NA

PE (Forward)	22.86
PEG Ratio	NA
Current Year Est.	1.92
Current Quarter Estimate	NA
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	05-16-2013
EPS Last Year	1.75
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Eisai Co Ltd: (OTC: ESALY)

$43.90

-0.15 (-0.34%)

Volume 400

May 17 03:39 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description